Foghorn Therapeutics Inc (FHTX) — Who's Buying and Selling (13F, Q2 2026)

FHTX ranks #4489 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

105 institutions disclose a position in FHTX, but none treat it as a major bet — even Flagship Pioneering, LLC, its most concentrated holder, allocates just 4.0% of its own portfolio to it.

GAMMA Investing LLC has trimmed its FHTX position for two straight quarters, cutting it by $2.9K while still holding $1.2K.

FHTX is down 2.1% today, but institutions show net buying of $4.4M this quarter — a divergence between today's price move and the underlying institutional flow.

FHTX reported a net loss of $64.6M over the trailing twelve months.

• Not yet profitable — net loss of $64.6M over the trailing twelve months
• Revenue grew 52.0% year over year
• Net income improved year over year, from -$75.4M to -$64.6M
• Operating cash flow was negative, using $86.1M in cash
• Current ratio of 2.73x — enough short-term assets to cover short-term liabilities